We also showed that unselected PGT for a BC/OC gene panel (i.e., BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2) was more cost effective than current clinical criteria/FH-based testing approaches and can prevent thousands of OC/BC cases [26]. This evidence concerns the gene BRCA2 and breast cancer.